Gankyrin

Details Gankyrin Gankyrin

2005-03-21

2010-11-16

Schnizer, Richard (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S022100, C536S024100, C536S024500, C536S023500, C536S023100

Reexamination Certificate

active

07833988

ABSTRACT:
Gankyrin having the amino acid sequence as set forth in SEQ ID NO: 2, or modified gankyrin comprising an amino acid sequence modified by the deletion and/or addition of one or a plurality of amino acids and/or the substitution with other amino acids in the amino acid sequence of SEQ ID NO: 2 and retaining the biological activity of gankyrin, a gene encoding it, and a method of preparing said protein and uses thereof.

REFERENCES:
patent: 9-075085 (1997-03-01), None
Tamm et al., Lancet, Aug. 11, 2001;358(9280):489-97.
Kawakami, et al. (2007) Nonviral Approaches for Targeted Delivery of Plasmid DNA and Oligonucleotide. J. Pharm. Sci., v.97(2):726-745.
Baeuerle, et al., “Activation of DNA-Binding Activity in an Apparently Cytoplasmic Precursor of the NFκB Transcription Factor”,Cell, 1988, vol. 53, No. 2, pp. 211-217.
Belghiti et al.; “Intrahepatic Recurrence After Resection of Hepatocellular Carcinoma Complicating Cirrhosis”;Ann. Surg.; 1991; vol. 214, No. 2; pp. 114-117.
Bowie et al., “Deciphering the Message in Protein Sequences Tolerance to Amino Acid Substitutions,”,Science, 1990, vol. 247, pp. 1306-1310.
Burgess et al. “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue”,The Journal of Cell Biology, 1990, vol. 111, pp. 2129-2138.
Calvet et al.; “Prognostic Factor of Hepatocellular Carcinoma in the West: A Multivariate Analysis in 206 Patients”;Hepatology; 1990; vol. 12, No. 4; pp. 753-760.
Database EMBL Online, Est., 495 bp, Aug. 27, 1996, Retrieved from EBI Database Accession No. AA035825, 2 Sheets, XP002238075.
Dawson et al., “The 26S-proteasome: regulation and substrate recognition”Molecular Biology Reports, 1997, vol. 24, No. 1-2, pp. 39-44.
Decaprio, et al., “The Product of the Retinoblastoma Susceptibility Gene has Properties of a Cell Cycle Regulatory Element”,Cell, 1989, vol. 58, No. 6, pp. 1085-1095.
Demartino et al., “PA700, an ATP-dependent Activator of the 20 S Proteasome, Is an ATPase Containing Multiple Members of a Nucleotide-binding Protein Family.”,The Journal of Biological Chemistry, Aug. 19, 1994, vol. 269, No. 33, pp. 20878-20884.
Franco et al.; “Resection of Hepatocellular Carcinomas”;Gastroenterology; 1990; vol. 98, No. 3; pp. 733-738.
Furutani et al.; “Decreased Expression and Rare Somatic Mutation of the CIPI/WAFI Gene in Human Hepatocellular Carcinoma”;Cancer Letters; 1997; vol. 111, pp. 191-197.
Furutani et al.; “Kan-1 (Bile Acid CoA:Amino Acid N-Acyltransferase) Messenger RNA as a Novel Predictive Indicator for Prognosis of Hepatocellular Carcinoma Patients After Partial Hepatectomy”;Hepatology, 1996; vol. 24, No. 6; pp. 1441-1445.
Higashitsuji et al., “Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas”,Nature Medicine, Jan. 2000, vol. 6, No. 1, pp. 96-99.
Hori et al., “cDNA cloning and functional analysis of p28 (Nas6p) and p40.5 (Nas7p), two novel regulatory subunits of the 26S proteasome”,Gene, Aug. 1988, vol. 216, No. 1, pp. 113-122.
Jamsa et al., “Structural Features of a Polypeptide Carrier Promoting Secretion of a β-Lactamase Fusion Protein in Yeast”,Yeast, 1995, vol. 11, pp. 1381-1391.
Lambert et al., “cDNA sequence for human erythrocyte ankyrin”,Proc. Natl. Acad. Sci. USA, Mar. 1990, vol. 87, pp. 1730-1734.
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities”,Molecular and Cellular Biology, 1988, vol. 8, No. 3, pp. 1247-1252.
Mise et al.; “Clinical Significance of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Gene Expression in Liver Tumor”;Hepatology; 1996; vol. 23, No. 3; pp. 455-464.
Thompson et al., “Convergence of Ets- and Notch-Related Structral Motifs in a Heteromeric DNA Binding Complex”,Sciences, 1991, vol. 253, No. 5021, pp. 762-768.
Tobe et al.; “Prime Liver Cancer in Japan”; 1990; pp. 277-287.
Tobe et al.; “Prime Liver Cancer in Japan”; 1992; pp. 243-255.
Tobe et al.; “Prime Liver Cancer in Japan”; 1992; pp. 445-453.
Tobe et al.; Predictive Factors for Long Term Prognosis After Partial Hepatectomy for Patients With Hepatocellular Carcinoma in Japan;Cancer; 1994; vol. 74, No. 10; pp. 2772-2775.
Wang et al., “A Single Nuclease Active Site of theEscherichia coliRecBCD Enzyme Catalyzes Single-stranded DNA Degradation in Both Directions”,The Journal of Biological Chemistry, 2000, Vo. 275, No. 1, pp. 507-513.
Willardson et al., “Localization of the Ankyrin-binding Site on Erythrocyte Membrane Protein, Band 3”,J. Biol Chem., 1989, vol. 264, No. 27, pp. 15893-15899.
Zhang et al., “Expression and Functional Characterization ofEscherichia coliNusA and Lambda Q as Glutathione S-Transferase Fusion Proteins”,Protein Expression and Purification, 1995, vol. 6, pp. 625-631.
Lozano et al., “Gankyrin: An intriguing name for a novel regulator of p53 and RB,” Cancer Cell, Jul. 3-4, 2005.

Affiliated with

Also associated with

Rating

Gankyrin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gankyrin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gankyrin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4161295